Balyasny Asset Management
KYNB

Balyasny Asset Management’s Kyntra Bio KYNB Stock Holding History

Balyasny Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-800
Closed -$822K – 1444
2020
Q3 		$822K Buy
+800
New +$861K 0.01% 1038
2019
Q2 		– Sell
-5,040
Closed -$6.85M – 1555
2019
Q1 		$6.85M Buy
+5,040
New +$6.84M 0.05% 488

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Balyasny Asset Management's KYNB Position: Q3 2024 in Review

Balyasny Asset Management sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 776 shares — an estimated $17.3K sold.

Balyasny Asset Management first reported a position in KYNB in Q4 2014 and held it in 7 quarters. The position peaked at $1.01M in Q2 2023. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Balyasny Asset Management reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 776 Kyntra Bio shares in Q3 2024, an estimated $17.3K.
  • Balyasny Asset Management first reported a position in Kyntra Bio in Q4 2014 and held it in 7 quarters.
  • Balyasny Asset Management's Kyntra Bio position peaked at $1.01M in Q2 2023.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.